Albany, NY -- (SBWIRE) -- 11/01/2019 -- Gastrointestinal Stromal Tumors Market Insights, Epidemiology and Market Forecast-2028

1. Gastrointestinal Stromal Tumors annual incidence quoted in the United Kingdom ranges from 1.32 to 1.50 per 100,000 population, which is equivalent to approximately 800–900 new cases each year.
2. Gastrointestinal Stromal Tumors are rare tumors, with an estimated incidence of 1.5 per 100,000 per year in Europe.
3. Approximate annual Gastrointestinal Stromal Tumors incidence in Japan is 1500–2000 cases.

(Albany, US) DelveInsight launched a new report on Gastrointestinal Stromal Tumors Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Gastrointestinal Stromal Tumors market report covers a descriptive overview and comprehensive insight of the Gastrointestinal Stromal Tumors epidemiology and Gastrointestinal Stromal Tumors market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Gastrointestinal Stromal Tumors market report provides insights into current and emerging therapies.
3. Gastrointestinal Stromal Tumors market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Gastrointestinal Stromal Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Gastrointestinal Stromal Tumors market.

Request for sample pages

"The total number of Gastrointestinal Stromal Tumors cases in the United States range from about 4000 to about 6000 each year."

Surgery remains the mainstay therapy for resectable primary Gastrointestinal Stromal Tumors, provided there is no evidence of metastases. The goal of surgery is complete resection of visible and microscopic disease. Neo-adjuvant Imatinib is considered for "functionally unresectable" Gastrointestinal Stromal Tumors, where surgery would result in significant morbidity or loss of organ function. In some patients with primary Gastrointestinal Stromal Tumors, the tumor may be too large to remove or may require extensive resection of other organs.
Gastrointestinal Stromal Tumors tends to spread (metastasize) initially to the liver or to the lining of the abdomen (called the peritoneum). The initial metastatic Gastrointestinal Stromal Tumors treatment is currently imatinib mesylate.
The therapeutics Gastrointestinal Stromal Tumors market is totally governed by two products: Gleevec from Novartis is prescribed as the first line of drug therapy for unresectable and/or metastatic patients, and Sutent from Bayer forms the second line of drug therapy. These two agents are adequately catering to the needs of the specific patient group. Although the emerging agents are in early stages of development, and the combination of emerging agents and current therapies may be the way forward in satisfying the unmet needs in Gastrointestinal Stromal Tumors, they may prove more effective than mono-therapies, particularly for later line Gastrointestinal Stromal Tumors treatment.

The launch of the emerging therapies is expected to significantly impact Gastrointestinal Stromal Tumors treatment scenario in the upcoming years: -
Drugs covered
1. DCC-2618
2. Amcasertib
3. Avapritinib
And many others

The key players in Gastrointestinal Stromal Tumors market are:
1. Deciphera Pharmaceuticals
2. Boston Biomedical
3. Blueprint Medicines Corporation
And many others

Table of contents

1. Report Introduction
2. Gastrointestinal Stromal Tumors Market Overview at a Glance
3. Gastrointestinal Stromal Tumors Disease Background and Overview
4. Gastrointestinal Stromal Tumors Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Gastrointestinal Stromal Tumors 7MM Incident Cases (2017–2028 )
4.4. Gastrointestinal Stromal Tumors Total Patient Population by Regions
4.4.1. United States
4.4.2. EU5
4.4.2.1.Germany
4.4.2.2. Italy
4.4.2.3. Spain
4.4.2.4. France
4.4.2.5.United Kingdom
4.4.3. Japan
5. Gastrointestinal Stromal Tumors Current Treatment and Medical Practices
6. Current Unmet Needs
7. Gastrointestinal Stromal Tumors Marketed Drugs
7.1. Key Cross Competition Marketed Drugs
7.2. Stivarga (Regorafenib): Bayer HealthCare
8. Gastrointestinal Stromal Tumors Emerging Therapies
8.1. Key Cross Competition
8.2. DCC-2618: Deciphera Pharmaceuticals
8.3. Avapritinib: Blueprint Medicines Corporation
9. Gastrointestinal Stromal Tumors Market Outlook
10. Gastrointestinal Stromal Tumors 7MM Country-Wise Market Analysis (2017–2028 )
10.1. United States Market Size
10.2.Germany Market Size
10.3. France Market Size
10.4.United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan
11. Market drivers
12. Market barriers
13. Appendix
14. Gastrointestinal Stromal Tumors Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight